삼성서울병원

Ko En

Hematology-Oncology Lim, Ho Yeong M.D

Expertise
Liver cancer, biliary tract cancer
Treament Schedule 04 月
DATE
MON
01
TUE
02
WEB
03
THU
04
FRI
05
SAT
06
SUN
07
MON
08
TUE
09
WEB
10
THU
11
FRI
12
SAT
13
SUN
14
MON
15
TUE
16
WEB
17
THU
18
FRI
19
SAT
20
SUN
21
MON
22
TUE
23
WEB
24
THU
25
FRI
26
SAT
27
SUN
28
MON
29
TUE
30
AM
PM
Treament Schedule 05 月
DATE
WEB
01
THU
02
FRI
03
SAT
04
SUN
05
MON
06
TUE
07
WEB
08
THU
09
FRI
10
SAT
11
SUN
12
MON
13
TUE
14
WEB
15
THU
16
FRI
17
SAT
18
SUN
19
MON
20
TUE
21
WEB
22
THU
23
FRI
24
SAT
25
SUN
26
MON
27
TUE
28
WEB
29
THU
30
FRI
31
AM
PM

Medical Education

1998~2001 Ph.D. in Medicine Department of Pathology, Korea University College of Medicine, Seoul, Korea Awarded Ph.D. degree in Medicine
1978~1984 Master of Science Department of Medicine, Yonsei University College of Medicine, Seoul, Korea Awarded M.D. degree in Medicine

Post-Graduate Training

Fellowship   Yonsei Cancer Center, Yonsei University Severance Hospital
Residency   1985~1988 Yonsei University Severance Hospital
Internship   1984~1985 Yonsei University Medical Center, Seoul, Korea

Professional Appointments

2010~2011 Director Strategic Business Development Office of strategy & Planning Samsung Healthcare Group
2009~2011 Head Division of Hematology-Oncology, Department of Medicine Samsung Medical Center
2007~2010 Executive Director Samsung Clinical Research Institute
2006~present Professor Division of Hematology-Oncology, Department of Medicine Samsung Medical Center Sungkyunkwan University School of Medicine, Seoul, Korea
2003~2006 Director Clinical Research Center, Ajou University School of Medicine Suwon, Korea
2001~2006 Chairman Department of Hematology-Oncology, Ajou University School of Medicine Suwon, Korea
2004~2006 Professor Department of Hematology-Oncology, Ajou University School of Medicine
2000~2004 Associate Professor Department of Hematology-Oncology, Ajou University School of Medicine Suwon, Korea
1995~1997 Postdoctoral fellow Johns Hopkins University Oncology Center, Brady Urological Institute Baltimore, MD, U.S.A.
1995~2000 Assistant Professor Department of Hematology-Oncology, Ajou University School of Medicine Suwon, Korea
1993~1995 Instructor Department of Hematology-Oncology, Ajou University School of Medicine Suwon, Korea
1991~1993 Research Instructor Oncology Division, Yonsei Cancer Center, Department of Internal medicine, Yonsei University College of Medicine Seoul, Korea

Professional Memberships

Member Korean Association for Clinical Oncology
Member Korean Cancer Association
Member Korean Association of Internal Medicine
Member Korean Medical Association
Member Korean Cancer Study Group
Active member AACR (American Association of Cancer Research)
Active member ASCO (American Society of Clinical Oncology)

Selected Publications

  • BRIT J CANCER 2021 10.1038/s41416-021-01380-3 Randomised Phase 1b/2 trial of tepotinib vs sorafenib in Asian patients with advanced hepatocellular carcinoma with MET overexpression Ryoo1, BY; Cheng, AL; Ren, ZG; Kim, TY; Pan, HM; Rau, KM; Choi, HJ; Park, JW; Kim, JH; Yen, CJ; Lim, HY; Zhou, DL; Straub, J; Scheele, J; Berghoff, K; Qin, SK
    View PubMed
  • ADV THER 2021 10.1007/s12325-021-01700-2 Comparative Efficacy of Cabozantinib and Ramucirumab After Sorafenib for Patients with Hepatocellular Carcinoma and Alpha-fetoprotein >= 400 ng/mL: A Matching-Adjusted Indirect Comparison Trojan1, J; Mollon, P; Daniele, B; Marteau, F; Martin, L; Li, YX; Xu, Q; Piscaglia, F; Zaucha, R; Sarker, D; Lim, HY; Venerito, M
    View PubMed
  • LIVER CANCER 2021 10.1159/000515553 Pembrolizumab as Second-Line Therapy for Advanced Hepatocellular Carcinoma: A Subgroup Analysis of Asian Patients in the Phase 3 KEYNOTE-240 Trial Kudo1, M; Lim, HY; Cheng, AL; Chao, Y; Yau, T; Ogasawara, S; Kurosaki, M; Morimoto, N; Ohkawa, K; Yamashita, T; Lee, KH; Chen, ER; Siegel, AB; Ryoo, BY
    View PubMed
  • EUR UROL 2021 10.1016/j.eururo.2020.12.029 Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma: Final Overall Survival Analysis of the Phase 3 PROTECT Trial Motzer1, RJ; Russo, P; Haas, N; Doehn, C; Donskov, F; Gross-Goupil, M; Varlamov, S; Kopyltsov, E; Lee, JL; Lim, HY; Melichar, B; Zemanova, M; Rini, B; Choueirim, TK; Wood, L; Reaume, MN; Stenzl, A; Chowdhury, S; McDermott, R; Michael, A; Izquierdo, M; Aimone, P; Zhang, H; Sternberg, CN
    View PubMed
  • ONCOLOGY-BASEL 2021 10.1159/000514404 Programmed Death Ligand 1 Expression as a Prognostic Marker in Patients with Advanced Biliary Tract Cancer Kim1, H; Kim, J; Byeon, S; Jang, KT; Hong, JY; Lee, JY; Park, SH; Park, JO; Park, YS; Lim, HY; Kang, WK; Kim, ST
    View PubMed